NasdaqGS:GOSS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Gossamer Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GOSS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.7%

GOSS

-0.7%

US Biotechs

2.0%

US Market


1 Year Return

-38.1%

GOSS

23.4%

US Biotechs

7.1%

US Market

Return vs Industry: GOSS underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: GOSS underperformed the US Market which returned 7.1% over the past year.


Shareholder returns

GOSSIndustryMarket
7 Day-1.7%-0.7%2.0%
30 Day-6.7%3.3%6.0%
90 Day-4.4%14.4%-0.05%
1 Year-38.1%-38.1%24.6%23.4%9.5%7.1%
3 Yearn/a34.6%30.1%30.7%22.1%
5 Yearn/a-3.1%-8.9%55.6%38.0%

Price Volatility Vs. Market

How volatile is Gossamer Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Gossamer Bio undervalued compared to its fair value and its price relative to the market?

2.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GOSS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GOSS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GOSS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: GOSS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GOSS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GOSS is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Gossamer Bio forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-2.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GOSS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GOSS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GOSS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GOSS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GOSS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GOSS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Gossamer Bio performed over the past 5 years?

-64.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GOSS is currently unprofitable.

Growing Profit Margin: GOSS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GOSS is unprofitable, and losses have increased over the past 5 years at a rate of -64.4% per year.

Accelerating Growth: Unable to compare GOSS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GOSS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: GOSS has a negative Return on Equity (-65.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Gossamer Bio's financial position?


Financial Position Analysis

Short Term Liabilities: GOSS's short term assets ($355.4M) exceed its short term liabilities ($28.4M).

Long Term Liabilities: GOSS's short term assets ($355.4M) exceed its long term liabilities ($36.7M).


Debt to Equity History and Analysis

Debt Level: GOSS's debt to equity ratio (9.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GOSS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GOSS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GOSS has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 82.1% each year.


Next Steps

Dividend

What is Gossamer Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GOSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GOSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GOSS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GOSS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GOSS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Sheila Gujrathi (49yo)

1.83yrs

Tenure

US$6,245,606

Compensation

Dr. Sheila K. Gujrathi, M.D., is the Co-Founder and President of Gossamer Bio, Inc. since October 2015 and has been its Chief Executive Officer since July 23, 2018. Dr. Gujrathi has been a Director of Goss ...


CEO Compensation Analysis

Compensation vs Market: Sheila's total compensation ($USD6.25M) is above average for companies of similar size in the US market ($USD3.13M).

Compensation vs Earnings: Sheila's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Faheem Hasnain
Co-Founder & Chairman4.58yrsUS$1.55m4.46% $42.2m
Sheila Gujrathi
Co-Founder1.83yrsUS$6.25m5.34% $50.5m
Bryan Giraudo
Chief Financial Officer2yrsUS$2.65m0.034% $324.2k
Luisa Salter-Cid
Chief Scientific Officer1.75yrsUS$2.26m0.16% $1.5m
Christian Waage
Executive VP2.75yrsUS$867.30k0.70% $6.6m
Deanna Weber
Vice President of Human Resourcesno datano datano data
Richard Aranda
Senior Vice President of Clinical Developmentno datano datano data

1.9yrs

Average Tenure

52yo

Average Age

Experienced Management: GOSS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Faheem Hasnain
Co-Founder & Chairman4.58yrsUS$1.55m4.46% $42.2m
Sheila Gujrathi
Co-Founder1.83yrsUS$6.25m5.34% $50.5m
Russell Cox
Independent Director1.5yrsUS$337.44k0.0095% $89.8k
Thomas Daniel
Independent Director2.33yrsUS$327.44k0.050% $475.1k
Kristina Burow
Independent Director2.33yrsUS$329.94kno data
Joshua Bilenker
Independent Director1.42yrsUS$334.94kno data
Renée Galá
Independent Director1.42yrsUS$338.44kno data

2.3yrs

Average Tenure

49yo

Average Age

Experienced Board: GOSS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.


Top Shareholders

Company Information

Gossamer Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gossamer Bio, Inc.
  • Ticker: GOSS
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$945.000m
  • Shares outstanding: 75.78m
  • Website: https://www.gossamerbio.com

Number of Employees


Location

  • Gossamer Bio, Inc.
  • 3013 Science Park Road
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GOSSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2019
4GBMUN (Boerse Muenchen)YesCommon StockDEEURFeb 2019
4GBDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2019

Biography

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/27 10:00
End of Day Share Price2020/05/26 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.